Boundless Bio Inc(BOLD) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -2.86 | Insider Own | 23.06% | Shs Outstand | 22.5M | Perf Week | -0.82% |
| Market Cap | 0.05B | Forward P/E | - | EPS next Y | 61.26% | Insider Trans | 16.22% | Shs Float | 17.5M | Perf Month | -7.66% |
| Enterprise Value | -0.02B | PEG | - | EPS next Q | -0.56 | Inst Own | 57.31% | Short Float | 4.51% | Perf Quarter | -2.82% |
| Income | -0.06B | P/S | - | EPS this Y | 2.69% | Inst Trans | -2.33% | Short Ratio | 4.46 | Perf Half Y | 67.36% |
| Sales | 0.00B | P/B | 0.82 | EPS next 5Y | - | ROA | -50.56% | Short Interest | 0.79M | Perf YTD | 100.83% |
| Book/sh | 2.94 | P/C | 0.75 | EPS past 3/5Y | -8.04% -23.1% | ROE | -67.86% | 52W High | -23.82% ($3.16) | Perf Year | 61.74% |
| Cash/sh | 3.19 | P/FCF | - | Sales past 3/5Y | - | ROIC | -97.02% | 52W Low | 150.73% ($0.96) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 1.11% | Gross Margin | - | Volatility(W/M) | 3.82% 5.83% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.13 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 9.48 | EPS Q/Q | -50.51% | Profit Margin | - | RSI (14) | 40.7 | Recom | 3 |
| Dividend Gr. 3/5Y | - | Current Ratio | 9.48 | Sales Q/Q | - | SMA20 | -2.63% ($2.48) | Beta | 0.47 | Target Price | $4 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/08/17 | SMA50 | -10.25% ($2.69) | Rel Volume | 0.51 | Prev Close | $2.41 |
| Employees | 28 | LT Debt/Eq | 0 | EPS/Sales Surpr. | -4.04% - | SMA200 | 27.26% ($1.89) | Avg Volume(3M) | 0.18M | Price | $2.41 |
| IPO | 2024/3/28 | Option/Short | No/Yes | Trades | 825 | Volume | 91,090 | Change | - |
🧬 Boundless Bio () is a clinical-stage biotech developing a new class of cancer therapies that target extrachromosomal DNA (ecDNA). Its lead candidate, BBI-940, is an oral kinesin degrader with breast cancer as its primary indication.
Over the past 1 year, roughly in the middle
24% below its 1-year high.
Traded less than usual. That is 51% of its average volume.
BOLD has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +2.7% this year.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have paid off
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 57.3%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #406 of 594 in the industry
Based on market cap of $55M.
PTHS#405 Pelthos Therapeutics Inc $56M PER - BOLD#406 Boundless Bio Inc $55M PER - 
HYFT#407 MindWalk Holdings Corp $55M PER - 
INKT#408 MiNK Therapeutics Inc $54M PER - 
ALPS#409 ALPS Group Inc $54M PER - 
FAQ
What kind of company is BOLD?
BOLD belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of BOLD?
The market cap of BOLD is approximately $55M, ranking 4,798 within its sector.
What is the 52-week high and low for BOLD?
BOLD has recorded a 52-week high of $3.16 and a low of $0.96.
